Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Distinctive mRNA Signatures May Prove Diagnostic for Cancer-Related AIS

By LabMedica International staff writers
Posted on 22 Sep 2019
A recently published paper described a distinctive molecular signature present in blood mRNA expression profiles of patients with cancer-related acute ischemic stroke (AIS) that could potentially lead to earlier diagnosis of cancer in these patients.

Cancer is commonly diagnosed in patients with AIS. Since blood mRNA profiles can distinguish AIS mechanisms, a team of cancer investigators from several institutions including Weill Cornell Medical College (New York, NY, USA) and the University of California, Davis (USA) hypothesized that cancer-related AIS would have a distinctive gene expression profile.

To test this theory, the investigators evaluated four groups of 10 subjects prospectively enrolled at three centers from 2009 to 2018. This population included the group of interest with active solid tumor cancer and AIS and three control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable). Subjects in the vascular risk factor group were matched to subjects in the cancer-stroke and stroke-only groups by age, sex, and vascular risk factors. Blood was drawn 72 to 120 hours after stroke, and total RNA was analyzed using 3′ mRNA sequencing.

Results revealed that more than half of strokes in the cancer-stroke group were not caused by traditional risk factors. In total, more than 12,000 genes were analyzed and comparing the cancer-stroke group to the stroke-only group and after accounting for cancer-only genes, 438 genes were found to be differentially expressed. These genes were linked to upregulation of multiple genes/pathways implicated in autophagy signaling, immunity/inflammation, and gene regulation, including interleukin-1, interferon, relaxin, mammalian target of rapamycin signaling, SQSTMI1 (sequestosome-1), and CREB1 (cAMP response element binding protein-1).

"We clearly see that cancer-stroke patients have a unique gene expression profile," said first author Dr Babak Navi, chief of stroke and hospital neurology at Weill Cornell Medical College. "No one before had differentiated gene expression between patients with cancer, stroke, or both. A blood test would be easier, safer, and less expensive than a CT or PET scan to diagnose cancer."

The report was published in the September 12, 2019, online edition of the journal Stroke.

Related Links:
Weill Cornell Medical College
University of California, Davis


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.